Idiopathic Pulmonary Fibrosis

What is Pirfenidone for IPF?

An oral antifibrotic drug that slows the progression of idiopathic pulmonary fibrosis by inhibiting multiple fibrotic pathways. Combined with comprehensive ILD care, it extends life expectancy and preserves lung function.

Why China?

• Cost (annual): $2,500-$5,500 (domestic) vs. $95,000-$120,000 in the US
• Domestic production: Chinese-made pirfenidone + nintedanib at fraction of Western prices
• ILD expertise: China-Japan Friendship Hospital is Asia's leading ILD center
• Comprehensive management: Integrated pulmonary rehab + O2 therapy + transplant evaluation

Who is a candidate?

• Confirmed IPF (UIP pattern on HRCT or biopsy)
• FVC 50-80% predicted (disease-modifying window)
• ECOG 0-2
• Unexplained progressive fibrosing ILD (now also indicated)

Outcomes

FVC decline reduction: ~50%. Disease progression slowing: significant. Median survival extension: 1-2 years vs untreated. Common adverse effects: GI upset (30%), photosensitivity (20%) — usually manageable.